144881-52-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Benzyloxy-phenyl)-piperazine is used as a starting material for the synthesis of various drug candidates due to its chemical properties and pharmacological effects, which are beneficial in the development of antipsychotic and antidepressant medications.
Used in Research:
1-(4-Benzyloxy-phenyl)-piperazine is used as a research compound for studying its potential therapeutic effects on conditions such as depression, anxiety, and schizophrenia, given its activity as a serotonin receptor agonist.
Used in the Synthesis of Novel Psychoactive Substances:
Although it has potential medicinal applications, 1-(4-Benzyloxy-phenyl)-piperazine has also been identified as a precursor for the synthesis of novel psychoactive substances, which has raised concerns about its misuse and abuse in certain contexts.

Upstream product

• 110-85-0 piperazine 
• 6793-92-6 p-benzyloxyphenylbromide 
• 7700-27-8 4-chlorophenyl benzyl ether 
• 106-48-9 4-chloro-phenol 
• 946-80-5 (benzyloxy)benzene 
• 140681-55-6 Selectfluor 
• 100-39-0 benzyl bromide 
• 158985-25-2 tert-butyl 4-(4-hydroxyphenyl)piperazine-1-carboxylate 
• 943035-30-1 4-(4-benzyloxyphenyl)piperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1526935-46-5 (R)-1-(4-(2-(¹⁸F)fluoroethoxy)phenyl)-4-(4-(7-hydroxychroman-2-yl)-3-azabutyl)piperazine 
• 1526935-40-9 1-(4-benzyloxyphenyl)-4-(2-aminoethyl)piperazine 
• 1526935-41-0 (R)-1-(4-benzyloxyphenyl)-4-(4-(7-(methoxymethoxy)chroman-2-yl)-3-azabutyl)piperazine 
• 1526935-38-5 (R)-1-(4-hydroxyphenyl)-4-(4-(7-(methoxymethoxy)chroman-2-yl)-3-azabutyl)piperazine 
• 1526935-39-6 1-(4-benzyloxyphenyl)-4-(2-N-(tert-butylcarbamate)ethyl)piperazine 
• 56621-48-8 1-(4-hydroxyphenyl)piperazine 
• 1215855-23-4 acetic acid 3-{2-[4-(4-benzyloxy-phenyl)-piperazin-1-yl]-2-oxo-ethylcarbamoyl}-phenyl ester 
• 1215855-24-5 N-{2-[4-(4-benzyloxy-phenyl)-piperazin-1-yl]-2-oxo-ethyl}-3-hydroxy-benzamide 
• 1247040-87-4 C₂₁H₂₆N₂O₃ 
• 1215855-50-7 acetic acid 4-{4-[4-(4-benzyloxy-phenyl)-piperazin-1-yl]-4-oxobutyryl}-phenyl ester 
• 1215855-75-6 2-{4-[4-(benzyloxy)phenyl]piperazin-1-yl}-2-oxoethyl acetate 
• 1215855-59-6 {2-[4-(4-benzyloxy-phenyl)-piperazin-1-yl]-2-oxo-ethyl}-carbamic acid tert-butyl ester 
• 398458-41-8 2-[4-(4-benzyloxy-phenyl)piperazin-1-yl]-4,5-dihydroimidazo[4,5,1-ij]quinolin-6-one ethylene ketal 
• 144881-45-8 5-[4-(4-Benzyloxy-phenyl)-piperazin-1-ylmethyl]-4,5-dihydro-oxazol-2-ylamine 

Relevant academic research and scientific papers

MALIC ENZYME INHIBITORS

The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.

Charge-transfer-directed radical substitution enables para-selective C-H functionalization

Efficient C-H functionalization requires selectivity for specific C-H bonds. Progress has been made for directed aromatic substitution reactions to achieve ortho and meta selectivity, but a general strategy for para-selective C-H functionalization has remained elusive. Herein we introduce a previously unappreciated concept that enables nearly complete para selectivity. We propose that radicals with high electron affinity elicit arene-to-radical charge transfer in the transition state of radical addition, which is the factor primarily responsible for high positional selectivity. We demonstrate with a simple theoretical tool that the selectivity is predictable and show the utility of the concept through a direct synthesis of aryl piperazines. Our results contradict the notion, widely held by organic chemists, that radical aromatic substitution reactions are inherently unselective. The concept of radical substitution directed by charge transfer could serve as the basis for the development of new, highly selective C-H functionalization reactions.

Synthesis and characterization of a novel series of agonist compounds as potential radiopharmaceuticals for imaging dopamine D2/3 receptors in their high-affinity state

Imaging of dopamine D2/3 receptors (D2/3R) can shed light on the nature of several neuropsychiatric disorders in which dysregulation of D2/3R signaling is involved. Agonist D2/3 tracers for PET/SPECT imaging are considered to be superior to antagonists because they are more sensitive to dopamine concentrations and may selectively label the high-affinity receptor state. Carbon-11-labeled D2/3R agonists have been developed, but these short-lived tracers can be used only in centers with a cyclotron. Here, we report the development of a series of novel D2R agonist compounds based on the 2-aminomethylchromane (AMC) scaffold that provides ample opportunities for the introduction of longer-lived [ 18F] or [123I]. Binding experiments showed that several AMC compounds have a high affinity and selectivity for D2/3R and act as agonists. Two fluorine-containing compounds were [18F]-labeled, and both displayed specific binding to striatal D2/3R in rat brain slices in vitro. These findings encourage further in vivo evaluations.

RADIOLABELLING METHOD USING CYCLOALKYL GROUPS

This invention relates to novel cyclo alkyl compounds suitable for labeling by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

PIPERAZINE DERIVATIVES FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE

The invention relates to compounds of formula (I), their synthesis and their use, in particular for detecting amyloid deposits in a patient.

Mono N-arylation of piperazine(III): Metal-catalyzed N-arylation and its application to the novel preparations of the antifungal posaconazole and its advanced intermediate

A novel application of Pd0-catalyzed arylation to mono N-arylated piperazines, its mechanism, and its application towards the novel syntheses of the key differentially N,N′-diarylated piperazine antifungal intermediate N-(4-hydroxyphenyl)-N′-(4-aminophenyl)piperazine 5 as well as posaconazole 1 are described.